Pharming Group N.V.
PHARM.AS · AMS
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.29 | 0.02 | -0.15 |
| FCF Yield | 0.00% | 1.62% | -0.01% | 1.30% |
| EV / EBITDA | -0.06 | 77.08 | -151.23 | 49.03 |
| Quality | ||||
| ROIC | 2.37% | 1.90% | -2.66% | 0.86% |
| Gross Margin | 92.73% | 90.38% | 89.48% | 86.82% |
| Cash Conversion Ratio | 2.51 | 1.66 | -0.02 | 1.40 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.32% | 18.13% | 16.77% | 13.08% |
| Free Cash Flow Growth | 175.13% | 20,841.07% | -100.61% | -1.93% |
| Safety | ||||
| Net Debt / EBITDA | -0.06 | 3.70 | -14.37 | 3.67 |
| Interest Coverage | 1.99 | 2,712.25 | -1.38 | 5.37 |
| Efficiency | ||||
| Inventory Turnover | 0.11 | 0.14 | 0.14 | 0.22 |
| Cash Conversion Cycle | -100.75 | -95.64 | -47.63 | 384.92 |